Abstract
Glioblastoma, a highly lethal brain tumor, features extensive heterogeneity at the cellular and molecular levels. The discovery of glioma stem cells (GSCs) supports a new paradigm in tumor biology and therapeutic targeting. GSCs contribute to the cellular origin of primary gliomas and the recurrence of malignant gliomas after traditional treatments. A growing body of evidence suggests that GSCs, just as the bulk tumor cells, are heterogeneous with phenotypic and genetic complexity. Heterogeneous GSCs may add to glioblastoma heterogeneity and impact response to current therapies. A better understanding of GSC heterogeneity is required to facilitate the design of more effective therapies against this highly malignant brain tumor.
Keywords: Glioblastoma, glioma stem cells, heterogeneity.
Graphical Abstract
Current Signal Transduction Therapy
Title:The Heterogeneity of Glioma Stem Cells
Volume: 9 Issue: 2
Author(s): Suojun Zhang, Feng Wan, Lin Han, Fei Ye, Dongsheng Guo and Ting Lei
Affiliation:
Keywords: Glioblastoma, glioma stem cells, heterogeneity.
Abstract: Glioblastoma, a highly lethal brain tumor, features extensive heterogeneity at the cellular and molecular levels. The discovery of glioma stem cells (GSCs) supports a new paradigm in tumor biology and therapeutic targeting. GSCs contribute to the cellular origin of primary gliomas and the recurrence of malignant gliomas after traditional treatments. A growing body of evidence suggests that GSCs, just as the bulk tumor cells, are heterogeneous with phenotypic and genetic complexity. Heterogeneous GSCs may add to glioblastoma heterogeneity and impact response to current therapies. A better understanding of GSC heterogeneity is required to facilitate the design of more effective therapies against this highly malignant brain tumor.
Export Options
About this article
Cite this article as:
Zhang Suojun, Wan Feng, Han Lin, Ye Fei, Guo Dongsheng and Lei Ting, The Heterogeneity of Glioma Stem Cells, Current Signal Transduction Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574362409666140901225437
DOI https://dx.doi.org/10.2174/1574362409666140901225437 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Thiazolidinedione: A Privileged Scaffold for the Development of Anticancer Agents
Current Topics in Medicinal Chemistry Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Current Medicinal Chemistry Acetylome Regulation by Sirtuins in the Brain: From Normal Physiology to Aging and Pathology
Current Pharmaceutical Design Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Overview of Cantharidin and its Analogues
Current Medicinal Chemistry MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Reactions of Hydrazones with Lead Tetraacetate in Organic Synthesis
Current Organic Chemistry Biosynthetic Pathways to Glycosidase Inhibitors
Current Chemical Biology Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Stability Testing During Development of Nanopharmaceuticals
Pharmaceutical Nanotechnology Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine